According to a discussion on AcceleratedCure.org this video should contain interesting information regarding remylination or regeneration in MS.
It would be nice if someone could be so kind to give a short abstract about its contet.
http://www.tsr.ch/tsr/index.html?siteSe ... id=9654363
Thanks
--Frank
Someone fluent in french
Someone fluent in french
Treatment: Gilenya since 01/2011, CCSVI both IJV ballooned 09/2010, Tysabri stopped after 24 Infusions and positive JCV antibody test, after LDN, ABX Wheldon Regime for 1 year.
no can do, sorry. if there were a transcript i could pull it off but i can't hear the words clearly enough.
luckily the researchers' english is far better than my french:
http://www.geneuro.com/index2.php?rubID=25
GeNeuro develops therapeutic monoclonal antibodies to neutralize the immunopathogenic MSRV/HERV-W envelope proteins detected in MS brain plaques by independent studies, thus blocking the inflammatory cascade at the origin of brain lesions.
GeNeuro is developing humanized antibodies with external partners using state of the art technology. Those new antibodies will be soon evaluated with two animal models reproducing the MSRV/HERV-W envelope protein pathology developed with external collaborations before entering clinical trials within the next 2 years. The lead compound, GENHP-01 is in MS.
Following repeated transversal successful studies that validated the pathogenic MSRV/HERV-W envelope protein target in MS patients, a parallel longitudinal study is conducted on MS patients and will be completed before starting the clinical trials.
In addition, we are investigating the human endogenous retrovirus approach in the field of schizophrenia and other neurological diseases. Patients’ recruitment has already started.
luckily the researchers' english is far better than my french:
http://www.geneuro.com/index2.php?rubID=25
GeNeuro develops therapeutic monoclonal antibodies to neutralize the immunopathogenic MSRV/HERV-W envelope proteins detected in MS brain plaques by independent studies, thus blocking the inflammatory cascade at the origin of brain lesions.
GeNeuro is developing humanized antibodies with external partners using state of the art technology. Those new antibodies will be soon evaluated with two animal models reproducing the MSRV/HERV-W envelope protein pathology developed with external collaborations before entering clinical trials within the next 2 years. The lead compound, GENHP-01 is in MS.
Following repeated transversal successful studies that validated the pathogenic MSRV/HERV-W envelope protein target in MS patients, a parallel longitudinal study is conducted on MS patients and will be completed before starting the clinical trials.
In addition, we are investigating the human endogenous retrovirus approach in the field of schizophrenia and other neurological diseases. Patients’ recruitment has already started.
Re: Someone fluent in french
I don't speak French, but here's the Google translation of the sidebar text description of the video...
NHEGeneva: scientists experimenting with mice a drug against multiple sclerosis in plaques, 04 September 2008 19:30. A new molecule could treat multiple sclerosis. Tests on mice seem conclusive. This discovery took place in the structure called Eclosion, which promotes research in Geneva.
yep geneuro operating out of eclosion life sciences
http://www.eclosion.com/EN2/8_investiss ... eneuro.php
http://www.eclosion.com/EN2/8_investiss ... eneuro.php
Thanks for that 
!
Their effort looks promising to me, but at least its some different attempt compared to the common immunsupressive strategies.
--Frank
!Their effort looks promising to me, but at least its some different attempt compared to the common immunsupressive strategies.
--Frank
Treatment: Gilenya since 01/2011, CCSVI both IJV ballooned 09/2010, Tysabri stopped after 24 Infusions and positive JCV antibody test, after LDN, ABX Wheldon Regime for 1 year.